FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294833633> ?p ?o ?g. }

• W2294833633 endingPage "1389" @default.
• W2294833633 startingPage "1380" @default.
• W2294833633 abstract "Background. When combined with ceftazidime, the novel non–β-lactam β-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in 1066 men and women with complicated intra-abdominal infections from 2 identical, randomized, double-blind phase 3 studies (NCT01499290 and NCT01500239). Methods. The primary end point was clinical cure at test-of-cure visit 28–35 days after randomization, assessed by noninferiority of ceftazidime-avibactam plus metronidazole to meropenem in the microbiologically modified intention-to-treat (mMITT) population (in accordance with US Food and Drug Administration guidance), and the modified intention-to-treat and clinically evaluable populations (European Medicines Agency guidance). Noninferiority was considered met if the lower limit of the 95% confidence interval for between-group difference was greater than the prespecified noninferiority margin of −12.5%. Results. Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all primary analysis populations. Clinical cure rates with ceftazidime-avibactam plus metronidazole and meropenem, respectively, were as follows: mMITT population, 81.6% and 85.1% (between-group difference, −3.5%; 95% confidence interval −8.64 to 1.58); modified intention-to-treat, 82.5% and 84.9% (−2.4%; −6.90 to 2.10); and clinically evaluable, 91.7% and 92.5% (−0.8%; −4.61 to 2.89). The clinical cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was comparable to that with meropenem (mMITT population, 83.0% and 85.9%, respectively) and similar to the regimen's own efficacy against ceftazidime-susceptible infections (82.0%). Adverse events were similar between groups. Conclusions. Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatment of complicated intra-abdominal infections. Efficacy was similar against infections caused by ceftazidime-susceptible and ceftazidime-resistant pathogens. The safety profile of ceftazidime-avibactam plus metronidazole was consistent with that previously observed with ceftazidime alone. Clinical Trials Registration. NCT01499290 and NCT01500239." @default.
• W2294833633 created "2016-06-24" @default.
• W2294833633 creator A5015415938 @default.
• W2294833633 creator A5017669903 @default.
• W2294833633 creator A5051956832 @default.
• W2294833633 creator A5054829461 @default.
• W2294833633 creator A5062255591 @default.
• W2294833633 creator A5066279436 @default.
• W2294833633 creator A5074135663 @default.
• W2294833633 creator A5081263517 @default.
• W2294833633 creator A5084081858 @default.
• W2294833633 date "2016-03-08" @default.
• W2294833633 modified "2023-10-11" @default.
• W2294833633 title "Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program" @default.
• W2294833633 cites W1550111394 @default.
• W2294833633 cites W1895007034 @default.
• W2294833633 cites W1969500929 @default.
• W2294833633 cites W1992255321 @default.
• W2294833633 cites W2018229558 @default.
• W2294833633 cites W2023956015 @default.
• W2294833633 cites W2026414172 @default.
• W2294833633 cites W2048751517 @default.
• W2294833633 cites W2096913021 @default.
• W2294833633 cites W2097533517 @default.
• W2294833633 cites W2108565421 @default.
• W2294833633 cites W2113605290 @default.
• W2294833633 cites W2117154145 @default.
• W2294833633 cites W2122633654 @default.
• W2294833633 cites W2135825675 @default.
• W2294833633 cites W2137527487 @default.
• W2294833633 cites W2143074601 @default.
• W2294833633 cites W2147796775 @default.
• W2294833633 cites W2151923665 @default.
• W2294833633 cites W2153512397 @default.
• W2294833633 cites W2159554754 @default.
• W2294833633 cites W2167469281 @default.
• W2294833633 doi "https://doi.org/10.1093/cid/ciw133" @default.
• W2294833633 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4872289" @default.
• W2294833633 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26962078" @default.
• W2294833633 hasPublicationYear "2016" @default.
• W2294833633 type Work @default.
• W2294833633 sameAs 2294833633 @default.
• W2294833633 citedByCount "297" @default.
• W2294833633 countsByYear W22948336332015 @default.
• W2294833633 countsByYear W22948336332016 @default.
• W2294833633 countsByYear W22948336332017 @default.
• W2294833633 countsByYear W22948336332018 @default.
• W2294833633 countsByYear W22948336332019 @default.
• W2294833633 countsByYear W22948336332020 @default.
• W2294833633 countsByYear W22948336332021 @default.
• W2294833633 countsByYear W22948336332022 @default.
• W2294833633 countsByYear W22948336332023 @default.
• W2294833633 crossrefType "journal-article" @default.
• W2294833633 hasAuthorship W2294833633A5015415938 @default.
• W2294833633 hasAuthorship W2294833633A5017669903 @default.
• W2294833633 hasAuthorship W2294833633A5051956832 @default.
• W2294833633 hasAuthorship W2294833633A5054829461 @default.
• W2294833633 hasAuthorship W2294833633A5062255591 @default.
• W2294833633 hasAuthorship W2294833633A5066279436 @default.
• W2294833633 hasAuthorship W2294833633A5074135663 @default.
• W2294833633 hasAuthorship W2294833633A5081263517 @default.
• W2294833633 hasAuthorship W2294833633A5084081858 @default.
• W2294833633 hasBestOaLocation W22948336331 @default.
• W2294833633 hasConcept C126322002 @default.
• W2294833633 hasConcept C141071460 @default.
• W2294833633 hasConcept C168563851 @default.
• W2294833633 hasConcept C2775933652 @default.
• W2294833633 hasConcept C2776968632 @default.
• W2294833633 hasConcept C2777396551 @default.
• W2294833633 hasConcept C2777406300 @default.
• W2294833633 hasConcept C2777637488 @default.
• W2294833633 hasConcept C2779375183 @default.
• W2294833633 hasConcept C2908647359 @default.
• W2294833633 hasConcept C501593827 @default.
• W2294833633 hasConcept C523546767 @default.
• W2294833633 hasConcept C54355233 @default.
• W2294833633 hasConcept C71924100 @default.
• W2294833633 hasConcept C86803240 @default.
• W2294833633 hasConcept C89423630 @default.
• W2294833633 hasConcept C94665300 @default.
• W2294833633 hasConcept C99454951 @default.
• W2294833633 hasConceptScore W2294833633C126322002 @default.
• W2294833633 hasConceptScore W2294833633C141071460 @default.
• W2294833633 hasConceptScore W2294833633C168563851 @default.
• W2294833633 hasConceptScore W2294833633C2775933652 @default.
• W2294833633 hasConceptScore W2294833633C2776968632 @default.
• W2294833633 hasConceptScore W2294833633C2777396551 @default.
• W2294833633 hasConceptScore W2294833633C2777406300 @default.
• W2294833633 hasConceptScore W2294833633C2777637488 @default.
• W2294833633 hasConceptScore W2294833633C2779375183 @default.
• W2294833633 hasConceptScore W2294833633C2908647359 @default.
• W2294833633 hasConceptScore W2294833633C501593827 @default.
• W2294833633 hasConceptScore W2294833633C523546767 @default.
• W2294833633 hasConceptScore W2294833633C54355233 @default.
• W2294833633 hasConceptScore W2294833633C71924100 @default.
• W2294833633 hasConceptScore W2294833633C86803240 @default.
• W2294833633 hasConceptScore W2294833633C89423630 @default.
• W2294833633 hasConceptScore W2294833633C94665300 @default.

• next